Medtronic Announces First European Implant of New Drug-eluting Stent at Southampton General Hospital, UK

Resolute Integrity Stent Launched in the UK

WATFORD, England, September 7, 2010 - Medtronic, Inc. (NYSE: MDT), announces the CE (Conformite Europeene) mark
and international launch of the Resolute Integrity Stent System for the
treatment of coronary artery disease, a leading cause of death and poor
quality of life.

Now available in the UK, and implanted for the first time in Europe at
Southampton General Hospital, the Resolute Integrity Stent System features a
novel drug-eluting coronary stent with superior deliverability - the ability
of the device to traverse the patient's vasculature and reach the blockage in
the heart artery. Based on the engineering advance of continuous sinusoid
technology, the Resolute Integrity Stent System has been shown in bench
testing and in blinded in vivo physician assessment studies to be
significantly more deliverable than the current market-leading alternatives.

Coupled with the MicroTrac delivery system, continuous sinusoid
technology improves deliverability without compromising other important stent
design characteristics like radial strength. It also improves the stent's
conformability - the ability of the stent to conform to the natural shape of
the vessel and maintain apposition to the vessel wall after inflation with
the balloon catheter.

Medtronic offers a portfolio of bare-metal and drug-eluting stents to
address the spectrum of clinical need for patients with coronary artery
disease. The Resolute Integrity drug-eluting stent (DES) combines continuous
sinusoid technology with two key elements of the original Resolute DES: the
cytostatic antiproliferative drug zotarolimus and the highly biocompatible
BioLinx polymer.

"The Resolute Integrity Stent System provides superior deliverability and
powerful performance for complex daily practice," said Sean Salmon, vice
president and general manager of Medtronic's coronary and peripheral
division. "It offers physicians a compelling new treatment option for
patients with coronary artery disease."

Medtronic is committed to advancing the treatment of cardiovascular
disease through collaboration with leading clinicians, researchers and
scientists worldwide.

About Medtronic

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis,
is the global leader in medical technology - alleviating pain, restoring
health and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties
such as those described in Medtronic's periodic reports on file with the
Securities and Exchange Commission. Actual results may differ materially from
anticipated results.

Contact: Mikhaila Ellis, Public Relations, Tel : +44(0)7795-083-616, Email: mikhaila.d.ellis at medtronic.com